[Role of MCP-1 chemokine in the response of monocytes of patients with superficial tumors of the bladder treated with BCG immunotherapy].
Mechanism by which intravesical BCG treatment mediates antitumor activity are currently poorly understood. We initiated studies to determine the sequence and the factors that produce the immunological events. During the inflammatory answer a lot of molecules are produced. Chemokines MCP-1 and RANTES induces the mast-cell recruitment, that begins the "immunological fall". In our study 5 patients with superficial bladder cancer treated with BCG present an improvement of this cytokines correlated with a tumor-free status.
Iantorno
R
R
Clinica Urologica, Università degli Studi G. D'Annunzio, Chieti.
Nicolai
M
M
Cipollone
G
G
Di Federico
G
G
Tenaglia
R
R
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D018932:Chemokine CCL2 / Q000276:immunology*; D006801:Humans; D009000:Monocytes / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D018932:Chemokine CCL2